Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

被引：46
|
作者：
Rha, S. Y. [1 ]
Wyrwicz, L. S. [2 ]
Weber, P. E. Y. [3 ]
Bai, Y. [4 ]
Ryu, M. H. [5 ]
Lee, J. [6 ]
Rivera, F. [7 ]
Alves, G. V. [8 ]
Garrido, M. [9 ]
Shiu, K. -k. [10 ]
Fernandez, M. Gonzalez [11 ]
Li, J. [12 ]
Lowery, M. [13 ]
Cil, T. [14 ]
Cruz, F. J. S. M. [15 ]
Qin, S. [16 ]
Yin, L. [17 ]
Bordia, S. [18 ]
Bhagia, P. [18 ]
Oh, D-y. [19 ]
机构：
[1] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Internal Med, Seoul, South Korea
[2] Mar Sklodowska Curie Natl Res Inst Oncol, Oncol & Radiotherapy, Warsaw, Poland
[3] Univ La Frontera, James Lind Canc Res Ctr, Internal Med, Temuco, Chile
[4] Harbin Med Univ, Canc Hosp, Gastrointestinal Oncol, Harbin, Peoples R China
[5] Univ Ulsan, Asan Med Ctr, Oncol, Coll Med, Seoul, South Korea
[6] Sungkyunkwan Univ, Samsung Med Ctr SMC, Hematol & Oncol, Sch Med, Seoul, South Korea
[7] Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain
[8] Hosp Nossa Senhora Conceicao, Med Oncol, Porto Alegre, Brazil
[9] Univ Mayor, Oncol, Santiago, Chile
[10] Univ Coll Hosp NHS Fdn Trust, Oncol, London, England
[11] IMAT Oncomed, Monteria, Colombia
[12] Tongji Univ, Shanghai East Hosp, Med Oncol, Sch Med, Shanghai, Peoples R China
[13] Trinity St James Canc Inst, Med Oncol, Dublin, Ireland
[14] Hlth & Sci Univ, Adana City Hosp, Med Oncol, Adana, Turkiye
[15] Nucleo Pesquisa & Ensino Rede Sao Camilo, Med Oncol, Sao Paulo, Brazil
[16] Canc Ctr Peoples Liberat Army, Med Oncol, Nanjing, Peoples R China
[17] Merck & Co Inc, Biostat & Res Decis Sci, Rahway, NJ USA
[18] Merck & Co Inc, Global Clin Dev, Rahway, NJ USA
[19] Seoul Natl Univ, Internal Med, Coll Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷 / 03期
关键词：
D O I：
10.1016/j.annonc.2023.01.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：319 / 320
页数：2
相关论文
共 50 条
  • [31] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [32] Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study
    Shitara, K.
    Rha, S. Y.
    Wyrwicz, L. S.
    Oshima, T.
    Karaseva, N.
    Osipov, M.
    Yasui, H.
    Yabusaki, H.
    Afanasyev, S.
    Park, YK.
    Al-Batran, SE.
    Yoshikawa, T.
    Weber, P. E. Yanez
    Di Bartolomeo, M.
    Lonardi, S.
    Fang, X.
    Shih, CS.
    Bhagia, P.
    Bang, YJ.
    ANNALS OF ONCOLOGY, 2023, 34 : S1316 - S1316
  • [33] Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study
    Chung, H. C.
    Bang, Y-J.
    Tabernero, J.
    Van Cutsem, E.
    Fuchs, C. S.
    Wyrwicz, L.
    Lee, K-W.
    Kudaba, I.
    Garrido, M.
    Castro, H.
    Mansoor, W.
    Braghiroli, M. I.
    Goekkurt, E.
    Chao, J.
    Wainberg, Z. A.
    Kher, U.
    Shah, S.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] COST-EFFECTIVENESS OF PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC ESOPHAGEAL CANCER OR HER2-NEGATIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA IN FRANCE
    Aparicio, T.
    Mackosso, C.
    Cagnan, L.
    Bensimon, L.
    Tehard, B.
    Boussahoua, M.
    Zhang, S.
    Qu, T.
    Meng, Y.
    Francois, E.
    VALUE IN HEALTH, 2022, 25 (12) : S109 - S109
  • [35] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study.
    Shah, Manish A.
    Sun, Jong-Mu
    Shen, Lin
    Kato, Ken
    Enzinger, Peter C.
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Li, Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chul
    Mansoor, Wasat
    Li, Shau-Hsuan
    Sunpaweravong, Patrapim
    Maqueda, Maria Alsina
    Buchschacher, Gary L.
    Wu, Jimin
    Shah, Sukrut
    Bhagia, Pooja
    Metges, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 250 - 250
  • [36] First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
    Chung, Hyun Cheol
    Bang, Yung-Jue
    S Fuchs, Charles
    Qin, Shu-Kui
    Satoh, Taroh
    Shitara, Kohei
    Tabernero, Josep
    van Cutsem, Eric
    Alsina, Maria
    Cao, Zhu Alexander
    Lu, Jia
    Bhagia, Pooja
    Shih, Chie-Schin
    Janjigian, Yelena Y.
    FUTURE ONCOLOGY, 2021, 17 (05) : 491 - 501
  • [37] Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.
    Fuchs, Charles S.
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-Hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun Cheol
    Muro, Kei
    Goekkurt, Eray
    Mansoor, Wasat
    McDermott, Raymond S.
    Shacham-Shmueli, Einat
    Chen, Xinqun
    Kang, S. Peter
    Mayo, Carlos Alberto
    Ohtsu, Atsushi
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Phase II study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (pembro) in advanced gastric or gastroesophageal junction (GEJ) cancer
    Chau, I.
    Culm-Merdek, K.
    Bendell, J. C.
    Catenacci, D. V.
    Lee, J.
    Chaney, M. F.
    MacIntyre, S.
    Gopal, S.
    Santos, V. Chamberlain
    Youssoufian, H.
    Mockbee, C.
    Benjamin, L.
    Park, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1050 - S1051
  • [39] A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus Hermann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)
    Van Cutsem, E.
    Amonkar, M.
    Fuchs, C. S.
    Alsina, M.
    Ozguroglu, M.
    Bang, Y-J.
    Chung, H. C.
    Muro, K.
    Goekkurt, E.
    Benson, A.
    Sun, W.
    Wainberg, Z. A.
    Norquist, J.
    Chen, X.
    Shih, C-S.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 304 - 304
12345